Using an artificial intelligence system, researchers at MIT and elsewhere have developed a new Covid-19 vaccine that could be effective against current and future strains, reports Gwen Egan for Boston.com. “The vaccine differs from others currently on the market due to the portion of the virus being targeted,” writes Egan.
Boston Globe reporter Hiawatha Bray writes that MIT researchers have used an AI system to identify a potential new Covid-19 vaccine that may be effective against both current and future variants of the virus. “The new vaccine targets a portion of the COVID virus that is much less prone to evolve,” writes Bray. “That could potentially make it effective against many different versions of the virus, eliminating the need for routine booster shots.”
MIT researchers have developed a new approach to vaccines that uses “a machine learning twist [that] could put an end to boosters and seasonal variant shots,” reports Devin Coldewey for TechCrunch.
Aagya Mathur MBA ’18 co-founded Aavia, a daily ovarian hormone health guide, reports Matt Symonds for Forbes. “We started Aavia to give young people tools to understand how their hormones impact how they feel,” Mathur explains.
Researchers at MIT developed a system that uses artificial intelligence to help predict future risk of developing breast cancer, reports Poppy Harlow for CNN. What this work does “is identifies risk. It can tell a woman that you’re at high risk for developing breast cancer before you develop breast cancer,” says Larry Norton, medical director of the Lauder Breast Center at the Memorial Sloan Kettering Cancer Center.
Bloomberg reporter Tanaz Meghjani writes that MIT researchers created a new system to 3D print a customized replica of the human heart, which could help improve replacement valve procedures. The new system “mimics blood flow and pressure in individual diseased hearts, suggesting a way to predict the effects of various replacements and select the best fit, avoiding potential leakage and failure,” Meghjani writes.
MIT engineers have developed a new technique for 3D printing a soft, flexible, custom-designed replica of a patient’s heart, report Gabrielle Emanuel and Amy Sokolow for WBUR. The goal of the research is to “provide realistic models so that doctors, researchers and medical device manufacturers can use them in testing therapies for different types of heart disease,” Emanuel and Sokolow explain.
Aera Therapeutics, founded by Prof. Feng Zhang, is working to “debut a type of protein nanoparticle that it believes can be used to ferry all sorts of genetic medicines around the body,” reports Lisa Jarvis for Bloomberg.
Writing for Fortune, Prof. Elazer R. Edelman and Mike Mussallem of Edwards Lifesciences write that the backlog of deferred medical treatments caused by the Covid-19 pandemic and resulting long-term health consequences could impact public health for years. Edelman and Mussallem emphasize that “it is incumbent upon us to identify timely real-world evidence to elucidate the effects of policy changes so they can be adaptive and agile enough to provide access to critical interventions and procedures.”
Researchers at MIT and elsewhere are analyzing patients’ speech patterns to see if they can detect Lou Gehrig’s disease in its early stages, reports Ben Leonard, Ruth Reader, Carmen Paun and Erin Schumaker for Politico. “Catching it early and beginning treatment can improve patients’ quality of life and delay symptom onset,” they write.
Prof. Feng Zhang founded Aera Therapeutics, a startup working to deliver curative genetic medicine to hard-to-reach parts of the body, reports Ryan Cross for The Boston Globe. “If Aera’s approach works in people, it could broaden the reach of genetic therapies, which currently have limited clinical applications – partly because there aren’t enough methods for getting those medicines to hone in on the right cells,” writes Cross.
An ingestible, pill-shaped sensor module, which can pinpoint its location as it moves through the body, has been developed by researchers at MIT and Caltech, reports Andrew Paul for Popular Science. This method “could one day offer an effective means to assess issues like constipation, gastroesophageal reflux disease, and gastroparesis,” writes Paul.
A new smart pill the size of a quarter, developed by a team of researchers from MIT, Caltech and NYU, could one day help doctors more easily identify issues in a patient’s digestive tract. “Such a device could offer an alternative to more invasive procedures in humans, such as endoscopy, that are currently used to diagnose motility disorders,” writes Nina Massey for The Independent.
Prof. Gio Traverso and his colleagues at Caltech and NYU have developed a smart ingestible sensor that may offer a less invasive way to diagnose gastrointestinal disorders. “The hope is the device will allow doctors, armed with the exact location of a GI tract disruption, to better target care — and give patients a diagnostic option they can use at home,” reports Lizzy Lawler for STAT.
Researchers from MIT and Caltech have developed a pill-shaped ingestible sensor that can be monitored as it moves through the GI tract, allowing doctors to more easily diagnose gastrointestinal disorders, reports Brian Heater for TechCrunch. “The ability to characterize motility without the need for radiation, or more invasive placement of devices, I think will lower the barrier for people to be evaluated,” says Prof. Giovanni Traverso.